Teva Pharmaceuticals
TEVA
481 hedge funds and large institutions have $8.05B invested in Teva Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 177 increasing their positions, 132 reducing their positions, and 33 closing their positions.
118% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 33
46% more call options, than puts
Call options by funds: $371M | Put options by funds: $255M
34% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 132
31% more capital invested
Capital invested by funds: $6.16B → $8.05B (+$1.89B)
20% more funds holding in top 10
Funds holding in top 10: 20 → 24 (+4)
8% more funds holding
Funds holding: 447 → 481 (+34)
1.34% less ownership
Funds ownership: 52.26% → 50.92% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$233M |
| 2 |
GCM
Glenview Capital Management
New York
|
+$74.3M |
| 3 |
PC
PointState Capital
New York
|
+$64.3M |
| 4 |
PCM
Parsifal Capital Management
Greenwich,
Connecticut
|
+$63.6M |
| 5 |
Neuberger Berman Group
New York
|
+$50.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$359M |
| 2 |
Morgan Stanley
New York
|
-$139M |
| 3 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
-$101M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$85.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$81.9M |
TEVA Hedge Fund Activity: Q1 2024 in Review
481 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2024, worth a combined $8.05B — up 31% from $6.16B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new TEVA positions and 33 closed out — a net gain of 39 holders — while 177 added to existing stakes and 132 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $233M. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $359M.
- 481 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2024, up from 447 in Q4 2023.
- Funds reported $8.05B of Teva Pharmaceuticals stock for Q1 2024, up 31% quarter-over-quarter.
- 72 funds opened new Teva Pharmaceuticals positions in Q1 2024 and 33 closed out, a net change of +39 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $233M added.
- The largest Teva Pharmaceuticals seller in Q1 2024 was Harel Insurance Investments & Financial Services, an estimated $359M sold.
Based on aggregated 13F filings for Q1 2024.